Role of IL-10 in Urinary Bladder Carcinoma and Bacillus Calmette-Guerin Immunotherapy

P.,

doi:10.3844/ajisp.2012.1.9

Cited by 6 publications

(3 citation statements)

References 82 publications

(76 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, blocking IL-10 activity could enhance BCG induction of Th1 immunity and improve the outcome. Previous evidence suggested that IL-10 was upregulated in high-grade and advanced tumor stages [28] which confirms the findings of the current report. On the contrary, it has been shown that higher levels of IFN-γ might predict an enhanced T-cell mediated antitumor immune response and a better prognosis.…”

Section: Discussionsupporting

confidence: 93%

Value of Immunological Biomarkers in Early Prediction of Bacillus Calmette-Guerin Failure in High-Risk Non-muscle-invasive Bladder Cancer

Mohamed G.A. El-Gazzar,

Abol-Enein,

Amira Awadalla3

et al. 2023

ann urol oncol

View full text Add to dashboard Cite

Objectives To investigate the predictive value of different immunological markers on treatment outcomes after bacillus Calmette-Guerin (BCG) induction in high-risk non-muscle-invasive bladder cancer (NMIBC). Patients and Methods Patients who underwent transurethral resection of bladder tumors for NMIBC were assessed for study eligibility. Urine and blood samples were taken from patients at baseline (immediately before the first dose of induction). Urine samples were evaluated for interleukin (IL)-6, IL-8, IL-10, IL-11, and interferon- γ by solid-phase enzyme-linked immunosorbent assay (ELISA). Blood samples were evaluated for epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2) using quantitative reverse transcriptase-polymerase chain reaction analysis. Each marker was assessed in relation to tumor recurrence. Results Between June 2016 and December 2019, 160 patients were included. Tumor recurrence occurred in 47 (29.38%) patients over a median (IQR) follow-up of 24 (12: 49) months. Using univariate analysis, the following urinary cytokines were associated with higher recurrence: urinary IL-6, 8, 10, 11, and interferon-γ. Also, serum EGFR and HER2 were associated with higher recurrence. On multivariate Cox regression analysis, significant variables include HER2 [HR (95%CI): 2.675 (1.367-5.233), p= 0.004], and IL-11 [HR (95%CI): 0.889 (0.825-0.957), p= 0.002]. Conclusions Serum HER2 and urinary IL-11 could be applied in clinical practice to predict BCG failure in patients with high-risk NMIBC, so those patients could be offered other modalities (radical cystectomy) early with better survival. Further studies are recommended to establish their exact role.

show abstract

Section: Discussionsupporting

confidence: 93%

Value of Immunological Biomarkers in Early Prediction of Bacillus Calmette-Guerin Failure in High-Risk Non-muscle-invasive Bladder Cancer

Mohamed G.A. El-Gazzar,

Abol-Enein,

Amira Awadalla3

et al. 2023

ann urol oncol

View full text Add to dashboard Cite

show abstract

“…BCG for cancer immunotherapy activity may have its function enhanced by addition of IL10 blocking monoclonal antibody (Luo et al, 2012). Favaro et al (2012) published an interesting article where they compared and characterized the effects of intravesical BCG and/or staphylococcal enterotoxin B for non-muscle invasive bladder cancer.…”

Section: Active Therapiesmentioning

confidence: 99%

Immunological Processes in Cancer: A Link Between Inflammation and Immunity

Victorino¹,

Jeremias

Assunção³

2014

American Journal of Immunology

View full text Add to dashboard Cite

Cancer is a worldwide issue and one of the most relevant death causes in child and adults. There are several causes that can lead to cancer development. It is well known that inflammation is one known hallmark of cancer and it favors tumor cells growth. Several alterations in immunological and inflammatory processes are caused in response to tumor presence and both innate and adaptive immunity have effective mechanism to destroy tumor cells. Nevertheless, distinct tumor types developed mechanisms to evade anti-tumor immunological responses. Here, we revise researches regarding inflammation and immune response during cancer development, as well as cancer signaling pathways and immunotherapy that have been performed in Brazil. The better understanding of the mechanisms regarding cancer and immunological processes is of huge importance and it may support the development of new cancer targets.

show abstract

“…BCG for cancer immunotherapy activity may have its function enhanced by addition of IL10 blocking monoclonal antibody (Luo et al, 2012). Fávaro et al (2012) published an interesting article where they compared and characterized the effects of intravesical BCG and/or staphylococcal enterotoxin B for non-muscle invasive bladder cancer.…”

Section: Non-specific Therapiesmentioning

confidence: 99%